Kairos Pharma, LTD.

Over the past 90 days, Kairos Pharma (KAPA) has reported zero cyber incidents and zero red-flag 8-K filings related to bankruptcy, delisting, restatement, or officer departures. This clean near-term record provides a baseline, though low signal in a 90-day window does not eliminate underlying risk exposure. The full $49 Report extends analysis to 12 months of filing history, adds a dilution risk score, maps financing events and their timing, flags AI-detected anomalies in SEC language patterns, and contextualizes any 8-K activity within the company's strategic narrative. The full $49 Report adds these layers of historical and quantitative depth.